Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

A major trial testing multiple sclerosis drug evobrutinib failed in December last year. Merck, which previously predicted ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

At the core of this is a recovery for its life science unit, which dipped last year as its boom from components for Covid ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

Overall, the attraction of Pfizer as an investment is its level of diversification with several different growing drug ...

Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisor, ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...